CompletedNCT00406354
Atomoxetine for children with ADHD and oppositional behavior
About this title
Read the official source — NCT00406354Medication studyAges 6–17Germany
Understand this study
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
- Listed locations
- Berlin and 5 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Study information
Study start dateNovember 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 181
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Germany
- Age range
- From 6 Years to 17 Years
- Official registry ID
- NCT00406354
- Official title
Show the full official title
A Randomized, Double-Blind Comparison of Atomoxetine Versus Placebo in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Berlin · Düsseldorf · Fulda
3 more locations
- Hamburg
- Heppenheim an der Bergstrasse
- München
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine and Placebo.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-onset ADHD
A 6-month, open-label extension to a 40-week, randomized, double-blind, placebo-controlled, multicenter efficacy and safety study of Ritalin® LA in the treatment of adult patients with childhood-on...